HC Wainwright Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock

Eton Pharmaceuticals (NASDAQ:ETON) had its price target hoisted by stock analysts at HC Wainwright from $70.00 to $80.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright‘s price objective points to a potential upside of 69.67% from the company’s previous close.

A number of other research firms have also recently commented on ETON. Zacks Research upgraded Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 12th. B. Riley Financial reissued a “buy” rating and issued a $70.00 target price (up from $40.00) on shares of Eton Pharmaceuticals in a research report on Friday, August 14th. Canaccord Genuity Group boosted their price target on Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a “buy” rating in a research note on Friday, August 14th. Weiss Ratings upgraded Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a research note on Tuesday, September 22nd. Finally, Craig Hallum reaffirmed a “buy” rating and set a $78.00 price target on shares of Eton Pharmaceuticals in a research report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $74.00.

Eton Pharmaceuticals Price Performance

Shares of ETON opened at $47.15 on Friday. The firm has a fifty day simple moving average of $54.92 and a two-hundred day simple moving average of $36.26. The firm has a market cap of $1.35 billion, a PE ratio of 124.08 and a beta of 0.89. The company has a current ratio of 1.52, a quick ratio of 1.30 and a debt-to-equity ratio of 0.41. Eton Pharmaceuticals has a 1-year low of $14.27 and a 1-year high of $66.37.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.19. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%. The firm had revenue of $57.93 million for the quarter, compared to the consensus estimate of $41.98 million. On average, equities analysts anticipate that Eton Pharmaceuticals will post 1.13 EPS for the current year.

Insider Activity at Eton Pharmaceuticals

In related news, Director Paul V. Maier sold 50,000 shares of the stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the completion of the sale, the director owned 59,745 shares in the company, valued at approximately $3,529,137.15. This trade represents a 45.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider David Krempa sold 4,166 shares of Eton Pharmaceuticals stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $55.07, for a total transaction of $229,421.62. Following the sale, the insider owned 43,381 shares in the company, valued at approximately $2,388,991.67. The trade was a 8.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 79,166 shares of company stock valued at $4,809,672 over the last three months. 16.49% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Eton Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ETON. EcoR1 Capital LLC grew its position in Eton Pharmaceuticals by 7.0% in the first quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock worth $53,603,000 after acquiring an additional 141,394 shares in the last quarter. BlackRock Inc. bought a new position in Eton Pharmaceuticals in the 2nd quarter valued at $68,629,000. Nantahala Capital Management LLC purchased a new position in Eton Pharmaceuticals in the 2nd quarter worth about $42,569,426. Pillsbury Lake Capital LLC purchased a new position in shares of Eton Pharmaceuticals during the second quarter worth approximately $14,015,083. Finally, Panoramic Capital LLC bought a new stake in shares of Eton Pharmaceuticals during the second quarter valued at approximately $7,537,000. 27.86% of the stock is owned by institutional investors.

Eton Pharmaceuticals News Roundup

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Record Q3 product sales reached $57.9 million, up 158% year over year. Eton said it exceeded its $200 million annualized revenue run-rate goal five quarters ahead of schedule. Eton Q3 2026 financial results
• Positive Sentiment: The company raised its 2026 revenue outlook to more than $175 million, from more than $145 million, and lifted its adjusted EBITDA margin outlook to more than 40%, from more than 35%. Q3 adjusted EBITDA was $28.5 million, or 49% of revenue. Eton Q3 2026 financial results
• Positive Sentiment: Q3 fully diluted GAAP EPS was $1.06, versus the Zacks consensus estimate of $0.34; non-GAAP fully diluted EPS was $0.50. Revenue also exceeded analyst expectations of about $42 million. Eton Q3 earnings and revenues surpass estimates
• Positive Sentiment: Management highlighted growth and rare-disease pipeline progress, including preliminary ET-700 pilot-study results assessing copper absorption inhibition and gastrointestinal tolerability. The available report details do not specify the study findings. ET-700 pilot study announcement

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.